Oral Drug Ferriprox Approved to Treat Excess Iron

by Dr. Nithin Jayan on  November 01, 2011 at 2:19 PM Health In Focus
  •   Print
  •   Share
  •   Comments
  •  Text 
Ferriprox (deferiprone), an oral drug has been approved for treating Thalassemia patients with excess iron due to blood transfusions. Thalassemia, a genetic blood disorder that causes anemia, necessitates the affected patient to have frequent blood transfusions. This leads to a serious, often fatal condition called iron overload. Excess iron can have a number of deleterious effects on the body. The risk of developing liver disease, diabetes, arthritis, heart failure, or an abnormal heart rhythm is higher in patients with iron overload.

Transfusional iron overload is usually treated with chelation therapy. Chelation therapy uses chemical agents that can remove heavy metals from the body. The modality does not work for all patients. Ferriprox has been approved for use when chelation therapy is inadequate.

Data from 12 clinical studies in 236 patients were analysed. Patients participating in the study did not respond to previous iron chelation therapy. Deferiprone was found to bring a 20% decrease in serum ferritin, a protein that stores iron in the body for later use. The drug was found to successfully reduce ferritin levels in half of the patients in the study.

The U.S. Food and Drug Administration (FDA), has listed the following side effects of Ferriprox:

• Nausea

• Vomiting

• Abdominal and joint pain

• Urine discoloration (chromaturia)

• A decrease in the number of white blood cells (neutropenia)

• An increase in the level of a liver enzyme that may be indicative of tissue or liver damage at unsafe amounts

2% of patients treated with Ferriprox developed a serious and potentially life-threatening condition called agranulocytosis. The number of granulocytes (a type of white blood cell that fights infection) falls dangerously in agranulocytosis.

Further uses of the drug are being probed into. ApoPharma, the company behind Ferriprox, has committed to study the effect of the drug in patients with sickle cell disease who have transfusional iron overload.

Reference: U.S. Food and Drug Administration (FDA)

Source-Medindia

 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
News Categories:  
Men's Health Center

Health In Focus News

» Surgical Treatments of Male Stress Urinary Incontinence » Bullied Early Adolescents are Prone to Self Harm: BMJ Study
» Novel Artificial Devices in the Treatment of Male Urinary Incontinence » Chances of Birth Defects With Assisted Reproductive Technologies
» Antioxidant Food Database » Hypnosis Can Help Ease Pain
» Lenalidomide-based Regimens for Multiple Myeloma » Occurrence of Non-Communicable Diseases in Prisoners - An Overview
Read More >>